Bristol Myers Squibb CO Form 4 insider transactions

Theodore R. Samuels II, a Director at Bristol-Myers Squibb Co., acquired 1,080.147 Deferred Share Units as part of his compensation plan, increasing his beneficial ownership to 59,477.227 units.

Bristol Myers Squibb Director Phyllis R. Yale acquired 756.103 Deferred Share Units, increasing her beneficial ownership to 36,447.723 units, as part of her compensation plan.

Bristol Myers Squibb CEO Christopher S. Boerner has transferred 62,719 shares of common stock to a Spousal Lifetime Access Trust as part of a personal estate planning transaction.

A Bristol-Myers Squibb executive, Wendy Short Bartie, reported the vesting of restricted stock units and subsequent share transactions, including tax-related dispositions, on June 3, 2025.

Bristol Myers Squibb CEO Christopher S. Boerner has reported a transfer of 62,720 shares of common stock to a Spousal Lifetime Access Trust (SLAT) as part of an estate planning transaction.

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reported the sale of company stock by his spouse.

EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports transactions involving common stock and market share units.

Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, purchased 4,250 shares of BMY stock at $47.58 per share on April 25, 2025.

EVP Karin Shanahan reports acquisition and disposal of Bristol-Myers Squibb common stock and restricted stock units on April 1, 2025.

Director Phyllis Yale reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Director Theodore R. Samuels II reports acquisition of deferred share units convertible to common stock in Bristol-Myers Squibb Co.

Director Derica W. Rice acquired deferred share units in Bristol-Myers Squibb, convertible to common stock upon ceasing to be a director or at a specified future date.

Director Michael R. McMullen acquired deferred share units convertible to common stock in Bristol-Myers Squibb on March 31, 2025.

Peter J. Arduini, a director of Bristol-Myers Squibb, acquired deferred share units convertible to common stock on March 31, 2025.

Robert M. Plenge, EVP and Chief Research Officer at Bristol-Myers Squibb, reports multiple transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Gregory Scott Meyers, EVP, Chief Digital & Tech Officer at Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

EVP Karin Shanahan reports transactions involving Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports transactions involving common stock and derivative securities, including acquisitions, disposals, and vesting of market share units and performance shares.

EVP, Chief People Officer of Bristol-Myers Squibb, Amanda Poole Ahn, reports transactions involving common stock and market share/performance units.

EVP and General Counsel of Bristol-Myers Squibb, Sandra Leung, reports multiple transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb, reports the vesting and acquisition of common stock and market share units, as well as shares withheld for tax payments.

Phil M. Holzer, SVP and Controller of Bristol-Myers Squibb, filed a Form 4 detailing transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and distribution of performance shares.

Benjamin Hickey, President of RayzeBio Org., reports acquisition of market share and performance units in Bristol-Myers Squibb, according to a Form 4 filing.

EVP Cari Gallman reports transactions involving Bristol-Myers Squibb (BMY) common stock and derivative securities, including vesting of market share units and performance shares.

EVP and CFO David Elkins reports acquisition and disposal of Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

Christopher Boerner, CEO of Bristol-Myers Squibb, reports transactions involving company stock and derivative securities, including vesting of market share units and distribution of performance shares.

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the vesting of restricted stock units and subsequent tax withholding.

Bristol-Myers Squibb's CEO, Christopher Boerner, purchased 2,000 shares of the company's common stock at a price of $55.048 per share on February 20, 2025.

Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reported purchasing shares of the company's common stock on February 14, 2025.